⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

April 17, 2026Journal of Hepato-Biliary-Pancreatic Sciences

Timing of Adjuvant S‐1 Chemotherapy and Survival After Pancreatectomy for Pancreatic Cancer: An Ancillary Analysis of the JASPAC 01 Trial

Dongha Lee Yukiyasu Okamura Yoshihide Nanno Takuya Mizumoto Jun Ishida Naoto Gotohda Hirochika Toyama Akira Fukutomi Narikazu Boku Katsuhiko Uesaka

View at Publisher

Ask AI

Bookmark

Share

Key Points

The aim is to evaluate the impact of the timing of S-1 chemotherapy on survival after pancreatectomy for pancreatic cancer.
Analysis of the JASPAC 01 trial data
Focus on timing of S-1 chemotherapy initiation at 6-8 weeks post-surgery
Survival outcome measurements
S-1 chemotherapy started at 6-8 weeks after surgery is linked to better survival rates
Favorable outcomes suggest optimal timing can enhance treatment effectiveness

Implication

Analysis demonstrates improved survival outcomes with timely initiation of S-1 chemotherapy post-pancreatectomy.

Abstract

Initiation of S-1 AC at 6-8 weeks after pancreatectomy was associated with favorable survival outcomes.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Lee et al. (2026) studied this question.

synapsesocial.com/papers/69e5c38303c29399140294f3 https://doi.org/10.1002/jhbp.70117

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Delayed Initiation of S-1 Adjuvant Chemotherapy Impairs Survival in Patients With Curatively Resected Pancreatic CancerPrognostic Study · 2026
2Response to “Methodological Concerns on the Optimal Timing of Adjuvant S‐1 After Pancreatectomy”Original Research · 2026
3Methodological Concerns on the Optimal Timing of Adjuvant S‐1 After PancreatectomyOriginal Research · 2026
4Comparison of prognoses in pancreatic cancer patients receiving neoadjuvant therapy versus adjuvant therapy.Cohort Study · 2026
5Efficacy and safety of neoadjuvant S-1-based chemoradiotherapy in resectable and borderline- resectable pancreatic cancer: A long-term follow-up study2024

More related papers

Adjuvant S-1 vs. observation for resected biliary tract cancer: 5-year follow-up of the JCOG1202/ASCOT.2024
Is adjuvant chemotherapy associated with improved survival for patients with a complete pathological response to neoadjuvant chemotherapy for pancreatic adenocarcinoma?: A population-based analysis.2026
Efficacy and safety of the S-1, nab-paclitaxel, and gemcitabine triplet regimen in patients with resected pancreatic ductal adenocarcinoma2025

More from Journal of Hepato-Biliary-Pancreatic Sciences

Evaluation of Extrahepatic Bile Duct Resection as a Parenchyma‐Preserving Alternative in Bismuth I– II Perihilar Cholangiocarcinoma: A Comparative Single‐Center AnalysisMon,
Prognostic Impact of the C‐Reactive Protein–Albumin–Lymphocyte ( CALLY ) Index in Patients With Hepatocellular Carcinoma Undergoing Living Donor Liver TransplantationMon,